|
1
|
Brentnall T: Management strategies for
patients with hereditary pancreatic cancer. Curr Treat Options
Oncol. 6:437–445. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Riaz SP, Linklater KM, Page R, Peake MD,
Møller H and Lüchtenborg M: Recent trends in resection rates among
non-small cell lung cancer patients in England. Thorax. 67:811–814.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chambers A, Routledge T, Pilling J and
Scarci M: In elderly patients with lung cancer is resection
justified in terms of morbidity, mortality and residual quality of
life? Interact Cardiovasc Thorac Surg. 10:1015–1021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao Y and Gao HP: Prevalence and causes of
air pollution and lung cancer in Xuanwei city and Fuyuan County,
Yunnan province, China. Front Med. 6:217–220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
World Health Organization, . Cancer. Fact
Sheet No 297. http://www.who.int/mediacentre/factsheets/fs297/en/Accessed
March 20, 2015.
|
|
6
|
Lichtenstein P, Holm NV, Verksalo PK,
Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki
K: Environmental and heritable factors in the causation of
cancer-analyses of cohort of twins from Sweden, Denmark, and
Finland. N Engl J Med. 343:78–85. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
American Cancer Society, . Cancer Facts
& Figures 1993. http://www.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/Accessed
March 20, 2015.
|
|
8
|
Geneste O, Camus AM, Castegnaro M,
Petruzzelli S, Macchiarini P, Angeletti CA, Giuntini C and Bartsch
H: Comparison of pulmonary DNA adduct levels, measured by
32P-postlabelling and aryl hydrocarbon hydroxylase activity in lung
parenchyma of smokers and ex-smokers. Carcinogenesis. 12:1301–1305.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith KR, Samet JM, Romieu I and Bruce N:
Indoor air pollution in developing countries and acute lower
respiratory infection in children. Thorax. 55:518–532. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raaschou-Nielsen OR, Andersen ZJ, Hvidberg
M, Jensen SS, Ketzel M, Sørensen M, Loft S, Overvad K and
Tjønneland A: Lung cancer incidence and long-term exposure to air
pollution from traffic. Environ Health Perspect. 119:860–865. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mu L, Liu L, Niu R, Zhao B, Shi J, Li Y,
Swanson M, Scheider W, Su J, Chang SC, et al: Indoor air pollution
and risk of lung cancer among chinese female non-smokers. Cancer
Causes Control. 24:439–450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barone-Adesi F, Chapman RS, Silverman DT,
He X, Hu W, Vermeulen R, Ning B, Fraumeni JF Jr, Rothman N and Lan
Q: Risk of lung cancer associated with domestic use of coal in
Xuanwei, China: Retrospective cohort study. BMJ. 345:e54142012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
International Agency for Research on
Cancer, . IARC monographs on the evaluation of carinogenic risks to
humans. 2011.http://monographs.iarc.fr/ENG/Classification/Accessed
March 20, 2015.
|
|
14
|
Ohyama K, Ito T and Kanisawa M: The roles
of diesel exhaust-particle extracts and the promotive effects of
NO2 and/or SO2 exposure on rat lung
tumorigenesis. Cancer. 139:189–197. 1999.
|
|
15
|
Lee WJ, Teschke K, Kauppinen T, Andersen
A, Jäppinen P, Szadkowska-Stanczyk I, Pearce N, Persson B, Bergeret
A, Facchini LA, et al: Mortality from lung cancer in workers
exposed to sulfur dioxide in the pulp and paper industry. Environ
Health Perspect. 110:991–995. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Langseth H and Andersen A: Cancer
incidence among male pulp and paper workers in Norway. Scand J Work
Environ Health. 26:99–105. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pope CA III, Burnett RT, Thun MJ, Calle
EE, Krewski D, Ito K and Thurston GD: Lung cancer, cardiopulmonary
mortality, and long-term exposure to fine particulate air
pollution. JAMA. 287:1132–1141. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Braun MM, Caporaso NE, Page WF and Hoover
RN: Genetic component of lung cancer: Cohort study of twins.
Lancet. 344:440–443. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Neale MC and Cardon LR: Methodology for
genetic studies of twin and families. 1st. Kluwer Academic
Publishers; Dordrecht: pp. 237–238. 1992
|
|
20
|
Ahlbom A, Lichtenstein P, Malmström H,
Feychting M, Hemminki K and Pedersen NL: Cancer in twins: Genetic
and non-genetic familial risk factor. J Nat Canc Isnt. 89:287–293.
1997. View Article : Google Scholar
|
|
21
|
Carmelli D, Swan GE, Robinette D and
Fabsitz R: Genetic influence on smoking - a study of male twins. N
Engl J Med. 327:829–833. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coté ML, Liu M, Bonassi S, Neri M,
Schwartz AG, Christiani DC, Spitz MR, Muscat JE, Rennert G, Aben
KK, et al: Increased risk of lung cancer in individuals with a
family history of the disease: A pooled analysis from the
International lung cancer consortium. Eur J Cancer. 48:1957–1968.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bailey-Wilson JE, Amos CI, Pinney SM,
Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M,
Franklin W, et al: A major lung cancer susceptibility locus maps to
chromosome 6q23-25. Am J Hum Genet. 75:460–474. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mitsuuchi Y and Testa JR: Cytogenetics and
molecular genetics of lung cancer. Am J Med Genet. 115:183–188.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zochbauer-Muller ZS, Gazdar AF and Minna
JD: Molecular pathogenesis of lung cancer. Annu Rev Physiol.
64:681–708. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schenk T, Ackermann J, Brunner C, Schenk
P, Zojer N, Roka S and Drach J: Detection of chromosomal aneuploidy
by interphase fluorescence in situ hybridization in
bronchoscopically gained cells from lung cancer patients. Chest.
111:1691–1696. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang JU, Koo SH, Kwon KC, Park JW, Shin
SY, Kim JM and Jung SS: High frequency of genetic alterations in
non-small cell lung cancer detected by multi-target fluorescence in
situ hybridization. J Korean Med Sci. 22(Suppl): S47–S51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kettunen E, Salmenkivi K, Vuopala K,
Toljamo T, Kuosma E, Norppa H, Knuutila S, Kaleva S, Huuskonen MS
and Anttila S: Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24
are rare in sputum cells of individuals at high risk of lung
cancer. Lung Cancer. 54:169–176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luk C, Tsao MS, Bayani J, Shepherd F and
Squire JA: Molecular cytogenetic analysis of non-small cell lung
carcinoma by spectral karyotyping and comparative genomic
hybridization. Cancer Genet Cytogenet. 125:87–99. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu YJ, Dong XY, Shipley J, Zhang RG and
Cheng SJ: Chromosome 3 imbalances are the most frequent aberration
found in non-small cell lung carcinoma. Lung Cancer. 23:61–66.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Testa JR, Siegfried JM, Liu Z, Hunt JD,
Feder MM, Litwin S, Zhou JY, Taguchi T and Keller SM: Cytogenetic
analysis of 63 non-small cell lung carcinomas: Recurrent chromosome
alterations amid frequent and widespread genomic upheaval. Gene
Chrom Cancer. 11:178–194. 1994. View Article : Google Scholar
|
|
32
|
Toyooka S, Suzuki M, Tsuda T, Toyooka KO,
Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N,
et al: Dose effect of smoking on aberrant methylation in non-small
cell lung cancer. Int J Cancer. 110:462–464. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wistuba II, Berry J, Behrens C, Maitra A,
Shivapurkar N, Milchgrub S, Mackay B, Minna JD and Gazdar AF:
Molecular changes in the bronchial epithelium of patients with
small cell lung cancer. Clin Cancer Res. 6:2604–2610.
2000.PubMed/NCBI
|
|
34
|
Sato S, Nakamura Y and Tsuchiya E:
Difference of allelotype between squamous cell carcinoma and
adenocarcinoma of the lung. Cancer Res. 54:5652–5655.
1994.PubMed/NCBI
|
|
35
|
Osada H and Takahashi T: Genetic
alterations of multiple tumor suppressors and oncogenes in the
carcinogenesis and progression of lung cancer. Oncogene.
21:7421–7434. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Downward J: The RAS superfamily of small
GTP binding proteins. Trends Biochem Sci. 15:469–472. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Riely GJ, Kris MG, Rosenbaum D, Marks J,
Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, et al: Frequency
and distinctive spectrum of KRAS mutations in never smokers with
lung adenocarcinoma. Clin Cancer Res. 14:5731–5734. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodenhuis S and Slebos RJ: Clinical
significance of Ras oncogene activation in human lung cancer.
Cancer Res. 52:(Suppl 9). S2665–S2669. 1992.
|
|
39
|
Bethune G, Bethune D, Ridgway N and Xu Z:
Epidermal growth factor receptor (EGFR) in lung cancer: An overview
and update. J Thorac Dis. 2:48–51. 2010.PubMed/NCBI
|
|
40
|
Inamura K, Ninomiya H, Ishikawa Y and
Matsubara O: Is the epidermal growth factor receptor status in lung
cancers reflected in clinicopathologic features? Arch Pathol Lab
Med. 134:66–72. 2010.PubMed/NCBI
|
|
41
|
Zhou CC, Zhou SW, Pan H, Su B and Gao ZQ:
Detection of epidermal growth factor receptor mutations in
non-small cell lung cancer by real-time PCR using TaqMan-MGB
probes. Zhonghua Zhong Liu Za Zhi. 29:119–123. 2007.(In Chinese).
PubMed/NCBI
|
|
42
|
Gupta R, Dastane AM, Forozan F,
RileyPortuguez A, Chung F, Lopategui J and Marchevsky AM:
Evaluation of EGFR abnormalities in patients with pulmonary
adenocarcinoma: The need to test neoplasms with more than one
method. Mod Pathol. 22:128–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ladanyi M and Pao W: Lung adenocarcinoma:
Guiding EGFR-targeted therapy and beyond. Mod Pathol. 21:(Suppl 2).
S16–S22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sun S, Schiller JH and Gazdar AF: Lung
cancer in never smokers-a different disease. Nat Rev Cancer.
7:778–790. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin L, Asthana S, Chan E, Bandyopadhyay S,
Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, et al:
Mapping the molecular determinants of BRAF oncogene dependence in
human lung cancer. Proc Natl Acad Sci USA. 111:E748–E757. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tissot C, Couraud S, Tanguy R, Bringuier
PP, Girard N and Souquet PJ: Clinical characteristics and outcome
of patients with lung cancer harboring BRAF mutations. Lung Cancer.
91:23–28. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mar N, Vredenburgh JJ and Wasser JS:
Targeting HER2 in the treatment of non-small cell lung cancer. Lung
Cancer. 87:220–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shimamura T, Ji H, Minami Y, Thomas RK,
Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI and
Wong KK: Non-small cell lung cancer and Ba/F3 transformed cell
harboring the ERBB2 G776ins V_G/C mutations are sensitive to the
dual specific epidermal growth factor receptor and ERBB inhibitor
HKI-272. Cancer Res. 66:6487–6491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yamamoto H, Higasa K, Sakaguchi M, Shien
K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N,
et al: Novel germline mutation in the transmembrane domain of HER2
in familial lung adenocarcinomas. J Natl Can Inst. 106:djt3382014.
View Article : Google Scholar
|
|
51
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of transforming EML4-ALK fusion
gene non-small cell lung cancer. Nature. 448:561–566. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sasaki T, Rodig SJ, Chirieac LR and Jänne
PA: The biology and treatment of EML4-ALK non-small cell lung
cancer. Eur J Can. 46:1773–1780. 2010. View Article : Google Scholar
|
|
54
|
Cai W, Li X, Su C, Fan L, Zheng L, Fei K,
Zhou C, Manegold C and Bindert GC: ROS1 fusions in Chinese patients
with non-small-cell lung cancer. Ann Oncol. 24:1822–1827. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Takeuchi K, Soda M, Togashi Y, Suzuki R,
Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et
al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bergethon K, Shaw AT, Ou SH, Katayama R,
Lovly CM, McDonald NT, Massion PP, SiwakTapp S, Gonzalez A, Fang R,
et al: ROS1 rearrangements define a unique molecular class of lung
cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kohno T, Ichikawa H, Totoki Y, Yasuda K,
Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, et
al: KIF5B-RET fusion in lung adenocarcinoma. Nat Med. 18:375–377.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Lou
X, Wang L, Li H, Zhang Y, et al: RET fusions define a unique
molecular and clinic pathologic subtype of non-small-cell lung
cancer. J Clin Oncol. 30:4352–4359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Eng C: RET proto-oncogene in the
development of human cancer. J Clin Oncol. 17:380–393.
1999.PubMed/NCBI
|
|
60
|
Chao BH, Briesewitz R and Villalona-Calero
MA: RET fusion genes in non-small-cell lung cancer. J Clin Oncol.
30:4439–4441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bodner SM, Minna JD, Jensen SM, D'Amico D,
Carbone D, Mitsudomi T, Fedorok J, Buchhagen DL, Nau MM and Gazdar
AF: Expression of mutant p53 proteins in lung cancer correlates
with the class of p53 gene mutation. Oncogene. 7:743–749.
1992.PubMed/NCBI
|
|
62
|
Husgafvel-Pursiainen KH, Boffetta P,
Kannio P, Nyberg F, Pershagen G, Mukeria A, Constantinescu V,
Fortes C and Benhmou S: P53 Mutations and exposure to environmental
tobacco smoke in a multicenter study on lung cancer. Cancer Res.
60:2906–2911. 2000.PubMed/NCBI
|
|
63
|
Tammemagi MC, McLaughlin JR and Bull SB:
Meta-analyses of p53 tumor suppressor gene alterations and
clinicopathological features in resected lung cancers. Cancer
Epidemiol Biomark Prev. 8:625–634. 1999.
|
|
64
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Weiss GJ, Bemis LT, Nakajima E, Sugita M,
Birks DK, Robinson WA, VarellaGarcia M, Bunn PA Jr, Haney J,
Helfrich BA, et al: EGFR regulation by microRNA in lung cancer:
Correlation with clinical response and survival to gefitinib and
EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
He L, He X, Lim LP, Stanchina ED, Xuan Z,
Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumor suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Antoniou AC, Casadei S, Heikkinen T,
Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer
K, Fostira F, et al: Breast-cancer risk in families with mutations
in PALB2. N Engl J Med. 371:497–506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Thompson ER, Rowley SM, Sawyer S, kConFab,
Eccles DM, Trainer AH, Mitchell G, James PA and Campbell IG:
Analysis of RAD51D in ovarian cancer patients and families with a
history of ovarian or breast cancer. PloS One. 8:e547722013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Imyanitov EN and Moiseyenko VM: Drug
therapy for hereditary cancers. Hered Cancer Clin Pract. 9:52011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li X and Hemminki K: Inherited
predisposition to early onset lung cancer according to histological
type. Int J Cancer. 112:451–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lindor NM, McMaster ML, Lindor CJ and
Greene MH: National Cancer Institute, Division of Cancer
Prevention, Community Oncology and Prevention Trials Research
Group: Concise handbook of familial cancer susceptibility
syndromes-second edition. J Natl Cancer Inst Monogr. 38:1–93.
2008.
|
|
74
|
Wells SA Jr, Gosnell JE, Gagel RF, Moley
J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J and
Schlumberger M: Vandetanib for the treatment of patients with
locally advanced or metastatic hereditary medullary thyroid cancer.
J Clin Oncol. 28:767–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Imyanitov EN and Byrski T: Systemic
treatment for hereditary cancer: A 2012 update. Can Clin Pract.
11:22013.
|
|
76
|
Narod SA: BRCA mutations in the management
of breast cancer: The state of the art. Nat Rev Clin Oncol.
7:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Joosse SA, Brandwijk KI, Mulder L,
Wesseling J, Hannemann J and Nederlof PM: Genomic signature of
BRCA1 deficiency in sporadic basal-like breast tumors. Genes
Chromosomes Cancer. 50:71–81. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Half E, Bercovich D and Rozen P: Familial
adenomatous polyposis. Orphanet J Rare Dis. 4:222009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kennelly RP, Gryfe R and Winter DC:
Familial colorectal cancer: Patient assessment, surveillance and
surgical management. Eur J Surg Oncol. Jul 27–2016.(Epub ahead of
print). View Article : Google Scholar
|
|
80
|
Vilar E and Gruber SB: Microsatellite
instability in colorectal cancer-the stable evidence. Nat Rev Clin
Oncol. 7:153–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gaughan EM, Cryer SK, Yeap BY, Jackman DM
and Costa DB: Family history of lung cancer in never smokers with
non-small cell lung cancer and its association with tumor harboring
EGFR mutations. Lung Cancer. 79:193–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Liu P, Vikis HG, Wang D, Lu Y, Wang Y,
Schwartz AG, Pinney SM, Yang P, de Andrade M, Petersen GM, et al:
Familial aggregation of common sequence variants on 15q24-25.1 in
lung cancer. J Natl Cancer Inst. 100:1326–1330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wu AH, Fontham ET, Reynolds P, Greenberg
RS, Buffler P, Liff J, Boyd P and Correa P: Family history of
cancer and risk of lung cancer among lifetime non-smoking women in
the United States. Am J Epidemiol. 143:535–542. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Bromen K, Pohlabeln H, Jahn I, Ahrens W
and Jöckel KH: Aggregation of lung cancer in families: Results from
a population based case control study in Germany. Am J Epidemiol.
152:497–505. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Hemminki K, Dong C and Vaittinen P: Cancer
risks to spouses and offspring in the family-cancer database. Genet
Epidemiol. 20:247–257. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hemminki K and Li X: Familial risk for
lung cancer by histology and age of onset: Evidence for recessive
inheritance. Exp Lung Res. 31:205–215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jonsson S, Thorsteinsdottir U,
Gudbjartsson DF, Jonsson HH, Kristleifur K, Arnason S, Gudnason V,
Isaksson HJ, Hallgrimsson J, Gulcher JR, et al: Familial risk of
lung carcinoma in the icelandic population. JAMA. 292:2977–2983.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Jin T, Zhou X and He X: The general
measurement of genetic factors on lung cancer in Xuanwei, China.
Zhongguo Fei Ai Za Zhi. 4:354–356. 2001.(In Chinese). PubMed/NCBI
|
|
89
|
Jin Y, Xu Y, Xu M and Xue S: Increased
risk of cancer among relatives of patients with lung cancer in
China. BMC Cancer. 5:1462005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Socialstyrelsen, . Cancer Incidence in
Sweden 2000. http://www.socialstyrelsen.se/publikationer2002/2002-42-5Accessed
March 20, 2015.
|
|
91
|
Nitadori J, Inoue M, Iwasaki M, Otani T,
Sasazuki S, Nagai K and Tsugane S: Association between lung cancer
incidence and family history of lung cancer: Data from a
large-scale population-based cohort study, the JPHC study. Chest.
130:968–975. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Coté ML, Kardia SL, Wenzlaff AS,
Ruckdeschel JC and Schwartz AG: Risk of lung cancer among white and
black relatives of individuals with early-onset lung cancer. JAMA.
293:3036–3042. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Osann KE: Lung cancer in women: The
importance of smoking, family history of cancer and medical history
of respiratory diseases. Cancer Res. 51:4893–4897. 1991.PubMed/NCBI
|
|
94
|
Yu XJ, Yang MJ, Zhou B, Wang GZ, Huang YC,
Wu LC, Cheng X, Wen ZS, Huang JY, Zhang YD, et al: Characterization
of somatic mutations in air pollution-related lung cancer.
EBioMedicine. 2:583–590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Spitz MR, Amos CI, Dong Q, Lin J and Wu X:
The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both
for nicotine dependence and for lung cancer. J Natl Cancer Inst.
100:1552–1556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Hung RJ, McKay JD, Gaborieau V, Boffetta
P, Hashibe M, Zaridze D, Mukeria A, SzeszeniaDabrowska N, Lissowska
J, Rudnai P, et al: A susceptibility locus for lung cancer maps to
nicotinic acetylcholine receptor subunit genes on 15q25. Nature.
452:633–637. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
You M, Wang D, Liu P, Vikis H, James M, Lu
Y, Wang Y, Wang M, Chen Q, Jia D, et al: Fine mapping of chromosome
6q23-25 region in familial lung cancer families reveals RGS17 as a
likely candidate gene. Clin Cancer Res. 15:2666–2674. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Bell DW, Gore I, Okimoto RA, GodinHeymann
N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G,
Settleman J and Haber DA: Inherited susceptibility to lung cancer
may be associated with the T790M drug resistance mutation in EGFR.
Nat Genet. 37:1315–1316. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
99
|
Oxnard GR, Miller VA, Robson ME, Azzoli
CG, Pao W, Ladanyi M and Arcila ME: Screening for germline EGFR
T790M mutations through lung cancer genotyping. J Thorac Oncol.
7:1049–1052. 2012. View Article : Google Scholar : PubMed/NCBI
|
